- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01129986
A Post Marketing Clinical Study Utilizing DermaStream and Saline in Venous Ulcers
2. september 2013 opdateret af: EnzySurge
A Post Marketing Clinical Study Utilizing DermaStream and Saline for Safety and Efficacy in Venous Stasis Ulcers of the Lower Extremity
An open-label, prospective, controlled, two-step approach, post-marketing clinical study, applying DermaStream with saline streaming, in conjunction with a sustained multi-compression wrap, on healthy individuals and on patients with a venous stasis ulcer of the lower extremity.
Studieoversigt
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
15
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Arizona
-
Tucson, Arizona, Forenede Stater, 85724
- S.A.L.S.A
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
Group A:
- Must be male or female ≥18 years of age.
- Must be a healthy individual with intact skin
Group B:
- Must be male or female ≥18 years of age
- Must have a venous stasis ulcer between the knee and the ankle (including the lateral and medial malleolus). The ulcer must have the typical appearance of venous leg ulceration and the diagnosis of venous origin.
- Ankle Brachial Pressure Index of >0.8 -<=1.2
- Must have a venous leg ulcer between 3 cm up to 5.6 cm maximum and an ulcer duration of 60 days or greater prior to enrollment in the study
Exclusion Criteria:
Group A and Group B:
- Is unable to manage the self-treatment at home
- Is pregnant or is a nursing mother
- Is a woman of child bearing potential who is not using an adequate form of contraception (or abstinent)
- Is < 18 years of age
- With gross morbid obesity (i.e., a Body Mass Index ≥ 50)
- Has a known allergy to any of the drugs and/or dressings that are part of this protocol
- Has previously participated in this study
Group B:
- Has an ulcer that is deemed by the Investigator to be caused primarily by a medical condition other than venous insufficiency (e.g., diabetes, malignant ulceration [Marjolin's ulcer], vasculitis, etc.)
- Has evidence of current clinical infection although colonization is not an exclusion criterion (see definition section)
- Suffers from diabetes mellitus with HbA1c ≥ 10%
- Suffers from clinically significant arterial disease
- Has evidence of the ulcer and/or infection extending to the underlying muscle, tendon, or bone
- Has used any investigational drug(s)/device(s) within 30 days preceding screening or the physician or subject anticipates use of any of these treatments during the 2 weeks following start of the treatment portion of the study
- Has used or is anticipated to use any of the prohibited concomitant medications and treatments, as specified in study protocol, section 9.1.
- Suffers from a condition, other than venous insufficiency or venous hypertension which, in the opinion of the Investigator, would compromise the safety of the subject and/or the quality of the data.
- Suffers from a condition, other than venous insufficiency or venous hypertension which, in the opinion of the Investigator, would seriously interfere negatively with the normal wound healing process.
- Has laboratory values at screening outside ± 20% of the institution's normal range for any parameter other than HbA1c
- If laboratory values are outside ± 20% but the investigator deems the subject acceptable for enrollment, the Principal Investigator may approve the inclusion of the subject as long as there is no evidence of any comorbid condition where comorbidity could influence the trialIs using any of the prohibited concomitant medications or treatments.
- Wound surrounding skin not intact or has signs of active dermatitis or infection
- Wound over-bleeds
- Wound is severely ischemic
- Wound is larger than device aperture diameter
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dermastream
|
Five treatment days.
On each day DermaStream application for up to 4 hours of saline streaming.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of DermaStream application
Tidsramme: Up to 21 days
|
Reduction of slough tissue.
|
Up to 21 days
|
|
Adverse Events
Tidsramme: Up to 21 days
|
Incidence of investigational product related adverse events
|
Up to 21 days
|
|
Effect of DermaStream application
Tidsramme: Up to 21 days
|
Increase of granulation tissue
|
Up to 21 days
|
|
Effect of DermaStream application
Tidsramme: Up to 21 days
|
Pain recording on 1-10 scale
|
Up to 21 days
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Usability
Tidsramme: 1-5 days
|
Device malfunction reports and device replacements as measures of usability
|
1-5 days
|
|
Wound size
Tidsramme: Up to 21 days
|
Decrease in wound size at 2 weeks following last treatment day
|
Up to 21 days
|
|
Quality of Life
Tidsramme: Up to 21 days
|
Improved "Quality of Life" at 2 weeks following last treatment day
|
Up to 21 days
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Daniel Ihnat, S.A.L.S.A, Tucson Arizona
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juni 2009
Primær færdiggørelse (Faktiske)
1. juli 2010
Studieafslutning (Faktiske)
1. november 2011
Datoer for studieregistrering
Først indsendt
10. maj 2010
Først indsendt, der opfyldte QC-kriterier
24. maj 2010
Først opslået (Skøn)
25. maj 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
4. september 2013
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
2. september 2013
Sidst verificeret
1. juni 2011
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ENZ-DER-003-US
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .